Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 42

1.

Rasagiline for amyotrophic lateral sclerosis: A randomized, controlled trial.

Statland JM, Moore D, Wang Y, Walsh M, Mozaffar T, Elman L, Nations SP, Mitsumoto H, Fernandes JA, Saperstein D, Hayat G, Herbelin L, Karam C, Katz J, Wilkins HM, Agbas A, Swerdlow RH, Santella RM, Dimachkie MM, Barohn RJ; Rasagiline Investigators of the Muscle Study Group and Western ALS Consortium.

Muscle Nerve. 2018 Sep 7. doi: 10.1002/mus.26335. [Epub ahead of print]

PMID:
30192007
2.

Andersen-Tawil Syndrome.

Veerapandiyan A, Statland JM, Tawil R.

In: Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Stephens K, Amemiya A, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2018.
2004 Nov 22 [updated 2018 Jun 7].

3.

Electrical impedance myography in facioscapulohumeral muscular dystrophy: A 1-year follow-up study.

Mul K, Heatwole C, Eichinger K, Dilek N, Martens WB, Van Engelen BGM, Tawil R, Statland JM.

Muscle Nerve. 2018 Aug;58(2):213-218. doi: 10.1002/mus.26127. Epub 2018 Apr 17.

PMID:
29543984
4.

Using an onset-anchored Bayesian hierarchical model to improve predictions for amyotrophic lateral sclerosis disease progression.

Karanevich AG, Statland JM, Gajewski BJ, He J.

BMC Med Res Methodol. 2018 Feb 6;18(1):19. doi: 10.1186/s12874-018-0479-9.

5.

Facioscapulohumeral muscular dystrophy functional composite outcome measure.

Eichinger K, Heatwole C, Iyadurai S, King W, Baker L, Heininger S, Bartlett A, Dilek N, Martens WB, Mcdermott M, Kissel JT, Tawil R, Statland JM.

Muscle Nerve. 2018 Jan 30. doi: 10.1002/mus.26088. [Epub ahead of print]

PMID:
29381807
6.

Review of the Diagnosis and Treatment of Periodic Paralysis.

Statland JM, Fontaine B, Hanna MG, Johnson NE, Kissel JT, Sansone VA, Shieh PB, Tawil RN, Trivedi J, Cannon SC, Griggs RC.

Muscle Nerve. 2018 Apr;57(4):522-530. doi: 10.1002/mus.26009. Epub 2017 Nov 29. Review.

7.

An instrumented timed up and go in facioscapulohumeral muscular dystrophy.

Huisinga J, Bruetsch A, Mccalley A, Currence M, Herbelin L, Jawdat O, Pasnoor M, Dimachkie M, Barohn R, Statland J.

Muscle Nerve. 2018 Mar;57(3):503-506. doi: 10.1002/mus.25955. Epub 2017 Oct 6.

PMID:
28877559
8.

Facioscapulohumeral Muscular Dystrophy.

Statland JM, Tawil R.

Continuum (Minneap Minn). 2016 Dec;22(6, Muscle and Neuromuscular Junction Disorders):1916-1931. Review.

9.

Validity of the 6 minute walk test in facioscapulohumeral muscular dystrophy.

Eichinger K, Heatwole C, Heininger S, Stinson N, Matichak Stock C, Grosmann C, Wagner KR, Tawil R, Statland JM; FSHD Clinical Trials Research Network.

Muscle Nerve. 2017 Mar;55(3):333-337. doi: 10.1002/mus.25251. Epub 2016 Dec 5.

10.

A randomized controlled trial of methotrexate for patients with generalized myasthenia gravis.

Pasnoor M, He J, Herbelin L, Burns TM, Nations S, Bril V, Wang AK, Elsheikh BH, Kissel JT, Saperstein D, Shaibani JA, Jackson C, Swenson A, Howard JF Jr, Goyal N, David W, Wicklund M, Pulley M, Becker M, Mozaffar T, Benatar M, Pazcuzzi R, Simpson E, Rosenfeld J, Dimachkie MM, Statland JM, Barohn RJ; Methotrexate in MG Investigators of the Muscle Study Group.

Neurology. 2016 Jul 5;87(1):57-64. doi: 10.1212/WNL.0000000000002795. Epub 2016 Jun 15.

11.

Targeting protein homeostasis in sporadic inclusion body myositis.

Ahmed M, Machado PM, Miller A, Spicer C, Herbelin L, He J, Noel J, Wang Y, McVey AL, Pasnoor M, Gallagher P, Statland J, Lu CH, Kalmar B, Brady S, Sethi H, Samandouras G, Parton M, Holton JL, Weston A, Collinson L, Taylor JP, Schiavo G, Hanna MG, Barohn RJ, Dimachkie MM, Greensmith L.

Sci Transl Med. 2016 Mar 23;8(331):331ra41. doi: 10.1126/scitranslmed.aad4583.

12.

Electrical impedance myography in facioscapulohumeral muscular dystrophy.

Statland JM, Heatwole C, Eichinger K, Dilek N, Martens WB, Tawil R.

Muscle Nerve. 2016 Oct;54(4):696-701. doi: 10.1002/mus.25065. Epub 2016 May 25.

13.

Milder phenotype in facioscapulohumeral dystrophy with 7-10 residual D4Z4 repeats.

Statland JM, Donlin-Smith CM, Tapscott SJ, Lemmers RJ, van der Maarel SM, Tawil R.

Neurology. 2015 Dec 15;85(24):2147-50. doi: 10.1212/WNL.0000000000002217. Epub 2015 Nov 11.

14.

Amyotrophic Lateral Sclerosis Regional Variants (Brachial Amyotrophic Diplegia, Leg Amyotrophic Diplegia, and Isolated Bulbar Amyotrophic Lateral Sclerosis).

Jawdat O, Statland JM, Barohn RJ, Katz JS, Dimachkie MM.

Neurol Clin. 2015 Nov;33(4):775-85. doi: 10.1016/j.ncl.2015.07.003. Epub 2015 Sep 8. Review.

15.

Primary Lateral Sclerosis.

Statland JM, Barohn RJ, Dimachkie MM, Floeter MK, Mitsumoto H.

Neurol Clin. 2015 Nov;33(4):749-60. doi: 10.1016/j.ncl.2015.07.007. Epub 2015 Sep 8. Review.

16.

Patterns of Weakness, Classification of Motor Neuron Disease, and Clinical Diagnosis of Sporadic Amyotrophic Lateral Sclerosis.

Statland JM, Barohn RJ, McVey AL, Katz JS, Dimachkie MM.

Neurol Clin. 2015 Nov;33(4):735-48. doi: 10.1016/j.ncl.2015.07.006. Epub 2015 Sep 8. Review.

17.

Immunohistochemical Characterization of Facioscapulohumeral Muscular Dystrophy Muscle Biopsies.

Statland JM, Odrzywolski KJ, Shah B, Henderson D, Fricke AF, van der Maarel SM, Tapscott SJ, Tawil R.

J Neuromuscul Dis. 2015;2(3):291-299.

18.

Combined N-of-1 trials to investigate mexiletine in non-dystrophic myotonia using a Bayesian approach; study rationale and protocol.

Stunnenberg BC, Woertman W, Raaphorst J, Statland JM, Griggs RC, Timmermans J, Saris CG, Schouwenberg BJ, Groenewoud HM, Stegeman DF, van Engelen BG, Drost G, van der Wilt GJ.

BMC Neurol. 2015 Mar 25;15:43. doi: 10.1186/s12883-015-0294-4.

19.

A multi-center screening trial of rasagiline in patients with amyotrophic lateral sclerosis: Possible mitochondrial biomarker target engagement.

Macchi Z, Wang Y, Moore D, Katz J, Saperstein D, Walk D, Simpson E, Genge A, Bertorini T, Fernandes JA, Swenson A, Elman L, Dimachkie M, Herbelin L, Miller J, Lu J, Wilkins H, Swerdlow RH, Statland J, Barohn R; Western ALS (WALS) Rasagiline Study Group.

Amyotroph Lateral Scler Frontotemporal Degener. 2015;16(5-6):345-52. doi: 10.3109/21678421.2015.1026826. Epub 2015 Apr 2.

20.

Multiplex Screen of Serum Biomarkers in Facioscapulohumeral Muscular Dystrophy.

Statland J, Donlin-Smith CM, Tapscott SJ, van der Maarel S, Tawil R.

J Neuromuscul Dis. 2014;1(2):181-190.

21.

Muscle pathology grade for facioscapulohumeral muscular dystrophy biopsies.

Statland JM, Shah B, Henderson D, Van Der Maarel S, Tapscott SJ, Tawil R.

Muscle Nerve. 2015 Oct;52(4):521-6. doi: 10.1002/mus.24621. Epub 2015 Jun 18.

22.

Muscle channelopathies.

Statland J, Phillips L, Trivedi JR.

Neurol Clin. 2014 Aug;32(3):801-15, x. doi: 10.1016/j.ncl.2014.04.002. Epub 2014 May 9. Review.

PMID:
25037091
23.

Facioscapulohumeral muscular dystrophy.

Statland J, Tawil R.

Neurol Clin. 2014 Aug;32(3):721-8, ix. doi: 10.1016/j.ncl.2014.04.003. Epub 2014 May 15. Review.

24.

Restrictive lung involvement in facioscapulohumeral muscular dystrophy.

Scully MA, Eichinger KJ, Donlin-Smith CM, Tawil R, Statland JM.

Muscle Nerve. 2014 Nov;50(5):739-43. doi: 10.1002/mus.24218. Epub 2014 Sep 29.

25.

Muscle channelopathies: the nondystrophic myotonias and periodic paralyses.

Statland JM, Barohn RJ.

Continuum (Minneap Minn). 2013 Dec;19(6 Muscle Disease):1598-614. doi: 10.1212/01.CON.0000440661.49298.c8. Review.

26.

Myasthenia gravis: Five new things.

Statland JM, Ciafaloni E.

Neurol Clin Pract. 2013 Apr;3(2):126-133.

27.

Risk of functional impairment in Facioscapulohumeral muscular dystrophy.

Statland JM, Tawil R.

Muscle Nerve. 2014 Apr;49(4):520-7. doi: 10.1002/mus.23949. Epub 2014 Feb 10.

PMID:
23873337
28.

Non-dystrophic myotonia: prospective study of objective and patient reported outcomes.

Trivedi JR, Bundy B, Statland J, Salajegheh M, Rayan DR, Venance SL, Wang Y, Fialho D, Matthews E, Cleland J, Gorham N, Herbelin L, Cannon S, Amato A, Griggs RC, Hanna MG, Barohn RJ; CINCH Consortium.

Brain. 2013 Jul;136(Pt 7):2189-200. doi: 10.1093/brain/awt133. Epub 2013 Jun 13.

29.

The diagnosis and treatment of myotonic disorders.

Heatwole CR, Statland JM, Logigian EL.

Muscle Nerve. 2013 May;47(5):632-48. doi: 10.1002/mus.23683. Epub 2013 Mar 27. Review.

PMID:
23536309
30.

Coats syndrome in facioscapulohumeral dystrophy type 1: frequency and D4Z4 contraction size.

Statland JM, Sacconi S, Farmakidis C, Donlin-Smith CM, Chung M, Tawil R.

Neurology. 2013 Mar 26;80(13):1247-50. doi: 10.1212/WNL.0b013e3182897116. Epub 2013 Feb 27.

31.

Reevaluating measures of disease progression in facioscapulohumeral muscular dystrophy.

Statland JM, McDermott MP, Heatwole C, Martens WB, Pandya S, van der Kooi EL, Kissel JT, Wagner KR, Tawil R.

Neuromuscul Disord. 2013 Apr;23(4):306-12. doi: 10.1016/j.nmd.2013.01.008. Epub 2013 Feb 11.

32.

Mexiletine for symptoms and signs of myotonia in nondystrophic myotonia: a randomized controlled trial.

Statland JM, Bundy BN, Wang Y, Rayan DR, Trivedi JR, Sansone VA, Salajegheh MK, Venance SL, Ciafaloni E, Matthews E, Meola G, Herbelin L, Griggs RC, Barohn RJ, Hanna MG; Consortium for Clinical Investigation of Neurologic Channelopathies.

JAMA. 2012 Oct 3;308(13):1357-65. doi: 10.1001/jama.2012.12607.

33.

Emerging subspecialties in neurology: fellowship in experimental therapeutics of neurologic disease.

Statland JM, Griggs RC, Augustine EF.

Neurology. 2012 Sep 25;79(13):e106-8. No abstract available.

34.

A quantitative measure of handgrip myotonia in non-dystrophic myotonia.

Statland JM, Bundy BN, Wang Y, Trivedi JR, Raja Rayan D, Herbelin L, Donlan M, McLin R, Eichinger KJ, Findlater K, Dewar L, Pandya S, Martens WB, Venance SL, Matthews E, Amato AA, Hanna MG, Griggs RC, Barohn RJ; CINCH Consortium.

Muscle Nerve. 2012 Oct;46(4):482-9. doi: 10.1002/mus.23402.

35.

Facioscapulohumeral muscular dystrophy: molecular pathological advances and future directions.

Statland JM, Tawil R.

Curr Opin Neurol. 2011 Oct;24(5):423-8. doi: 10.1097/WCO.0b013e32834959af. Review.

PMID:
21734574
36.

An interactive voice response diary for patients with non-dystrophic myotonia.

Statland JM, Wang Y, Richesson R, Bundy B, Herbelin L, Gomes J, Trivedi J, Venance S, Amato A, Hanna M, Griggs R, Barohn RJ; Cinch Consortium.

Muscle Nerve. 2011 Jul;44(1):30-5. doi: 10.1002/mus.22007.

37.

Primary lateral sclerosis.

Singer MA, Statland JM, Wolfe GI, Barohn RJ.

Muscle Nerve. 2007 Mar;35(3):291-302. Review.

PMID:
17212349
38.

Somatodendritic Kv7/KCNQ/M channels control interspike interval in hippocampal interneurons.

Lawrence JJ, Saraga F, Churchill JF, Statland JM, Travis KE, Skinner FK, McBain CJ.

J Neurosci. 2006 Nov 22;26(47):12325-38.

39.

Muscarinic receptor activation tunes mouse stratum oriens interneurones to amplify spike reliability.

Lawrence JJ, Grinspan ZM, Statland JM, McBain CJ.

J Physiol. 2006 Mar 15;571(Pt 3):555-62. Epub 2006 Jan 26.

40.

Cell type-specific dependence of muscarinic signalling in mouse hippocampal stratum oriens interneurones.

Lawrence JJ, Statland JM, Grinspan ZM, McBain CJ.

J Physiol. 2006 Feb 1;570(Pt 3):595-610. Epub 2005 Dec 1.

41.

Motor neuron firing dysfunction in spastic patients with primary lateral sclerosis.

Floeter MK, Zhai P, Saigal R, Kim Y, Statland J.

J Neurophysiol. 2005 Aug;94(2):919-27. Epub 2005 Apr 13.

42.

Primary lateral sclerosis: A heterogeneous disorder composed of different subtypes?

Zhai P, Pagan F, Statland J, Butman JA, Floeter MK.

Neurology. 2003 Apr 22;60(8):1258-65.

PMID:
12707427

Supplemental Content

Loading ...
Support Center